Erik Harris Biography and Net Worth

Erik Harris serves as Executive Vice President and Chief Commercial Officer. He joined Ultragenyx in 2017 as Senior Vice President, Head of North American Commercial Operations, and was promoted to Chief Commercial Officer in June 2019. In his current role, he is responsible for all commercial operations in North America, Europe, and Latin America, and is a member of the company’s executive leadership team.

Prior to joining Ultragenyx in 2017, Mr. Harris spent six years at Crescendo Bioscience, a subsidiary of Myriad Genetics, Inc. At Crescendo he held various leadership positions, most recently as Vice President of Commercial, leading all aspects of marketing, sales, managed care and customer service. Mr. Harris previously served as Vice President of Pulmonology Marketing at Intermune, Inc. Earlier in his career he held positions in the commercial organizations at Elan Pharmaceuticals, Inc., Genentech, Inc., and Bristol-Myers Squibb Company. In addition to the Crysvita® and Mepsevii® launches, Mr. Harris has been involved in the launches of Tarceva®, Tysabri® and Vectra-DA®. To begin his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy.

Mr. Harris received his Masters of Business Administration at the Wharton School of Business, and Bachelor of Science at the United States Naval Academy.

What is Erik Harris' net worth?: The estimated net worth of Erik Harris is at least $2.31 million as of September 5th, 2023. Mr. Harris owns 51,281 shares of Ultragenyx Pharmaceutical stock worth more than $2,308,671 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Harris may own. Additionally, Mr. Harris receives an annual salary of $848,240.00 as EVP at Ultragenyx Pharmaceutical. Learn More about Erik Harris' net worth.
How old is Erik Harris?: Mr. Harris is currently 53 years old. There are 7 older executives and no younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical is Dr. Emil D. Kakkis M.D., Ph.D., Founder, President, CEO & Director, who is 64 years old. Learn More on Erik Harris' age.
What is Erik Harris' salary?: As the EVP of Ultragenyx Pharmaceutical Inc., Mr. Harris earns $848,240.00 per year. The highest earning executive at Ultragenyx Pharmaceutical is Dr. Emil D. Kakkis M.D., Ph.D., Founder, President, CEO & Director, who commands a salary of $1,370,000.00 per year. Learn More on Erik Harris' salary.
How do I contact Erik Harris?: The corporate mailing address for Mr. Harris and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Erik Harris' contact information.
Has Erik Harris been buying or selling shares of Ultragenyx Pharmaceutical?: Erik Harris has not been actively trading shares of Ultragenyx Pharmaceutical during the last quarter. Most recently, Erik Harris sold 6,000 shares of the business's stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $37.96, for a transaction totalling $227,760.00. Following the completion of the sale, the executive vice president now directly owns 51,281 shares of the company's stock, valued at $1,946,626.76. Learn More on Erik Harris' trading history.
Who are Ultragenyx Pharmaceutical's active insiders?: Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Mardi Dier (CFO), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?: During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 137,745 shares worth more than $5,325,628.52. The most recent insider tranaction occured on April, 18th when EVP Eric Crombez sold 142 shares worth more than $6,262.20. Insiders at Ultragenyx Pharmaceutical own 6.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.
Information on this page was last updated on 4/18/2024.

Erik Harris Insider Trading History at Ultragenyx Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/5/2023	Sell	6,000	$37.96	$227,760.00	51,281
6/19/2023	Sell	305	$48.20	$14,701.00	57,281
6/19/2022	Sell	295	$54.78	$16,160.10	36,160
3/1/2022	Sell	2,713	$66.62	$180,740.06
7/6/2021	Sell	375	$91.53	$34,323.75
6/21/2021	Sell	572	$94.96	$54,317.12	26,280
6/19/2021	Sell	437	$94.63	$41,353.31	26,280
4/20/2021	Sell	396	$104.28	$41,294.88

Erik Harris Buying and Selling Activity at Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $45.11

$43.13

$45.58

50 Day Range

MA: $47.95

$42.31

$53.69

2 Week Range

Now: $45.11

$31.52

$54.98

Volume

836,694 shs

Average Volume

763,528 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

Erik Harris Biography and Net Worth

What is Erik Harris' net worth?

How old is Erik Harris?

What is Erik Harris' salary?

How do I contact Erik Harris?

Has Erik Harris been buying or selling shares of Ultragenyx Pharmaceutical?

Who are Ultragenyx Pharmaceutical's active insiders?

Are insiders buying or selling shares of Ultragenyx Pharmaceutical?